Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with stemness from human ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 8, 2013, Pages 1367-1375

  Du, Yong Rui ^a,b   Chen, Ying ^a   Gao, Yan ^a   Niu, Xiu Long ^a   Li, Ya Jing ^a   Deng, Wei Min ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Central Hospital for Obstetrics and Gynecology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; FLUORESCEIN ISOTHIOCYANATE; HERMES ANTIGEN; LIPOCORTIN 5; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A3D8; PROPIDIUM IODIDE; PROTEIN BCL 2; PROTEIN P21; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPHERE FORMING CELL; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; APOPTOSIS; ASCITES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION; HUMANS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84888257780     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a1d023     Document Type: Article

References (29)

1. Pecorelli S, Favalli G, Zigliani L, et al. Cancer in women. Int J Gynaecol Obstet. 2003;82:369-379.
2. Bapat SA. Human ovarian cancer stem cells. Reproduction. 2010;140:33-41.
3. Moserle L, Indraccolo S, Ghisi M, et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008;68:5658-5668.
4. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311-4320.
5. Auzenne E, Ghosh SC, Khodadadian M, et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia. 2007;9:479-486.
6. Chao GU, YongRui DU, Yan GAO, et al. Anti-CD44 mAb remodels biological behaviors of spheroid cells with stemness from human ovarian cancer cell line SKOV-3. Chin Sci Bull. 2012;57:1288-1298.
7. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
8. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/ progenitor cell properties. Cancer Res. 2005;65:5506-5511.
9. Morfouace M, Lalier L, Bonnamain V, et al. Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem. 2012;287:33664-33674.
10. Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008;5:474-486.
11. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153-166.
12. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158-10163.
13. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
14. Palapattu GS, Wu C, Silvers CR, et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate. 2009;69:787-798.
15. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 2008;26:725-733.
16. Ali HR, Dawson SJ, Blows FM, et al. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res. 2011;13:R118.
17. Herishanu Y, Gibellini F, Njuguna N, et al. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma. 2011;52:1758-1769.
18. Charrad RS, Li Y, Delpech B, et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med. 1999;5:669-676.
19. Maquarre E, Artus C, Gadhoum Z, et al. CD44 ligation induces apoptosis via caspase-and serine protease-dependent pathways in acute promyelocytic leukemia cells. Leukemia. 2005;19:2296-2303.
20. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342-348.
21. Zada AA, Singh SM, Reddy VA, et al. Downregulation of c-jun expression and cell cycle regulatory molecules in acute myeloid cells upon CD44 ligation. Oncogene. 2003;22:2296-2308.
22. King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem. 1995;58:175-180.
23. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410:549-554.
24. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:3-14.
25. Walsh V, Goodman J. Cancer chemotherapy, biodiversity, public and private property: the case of the anti-cancer drug taxol. Soc Sci Med. 1999;49:1215-1225.
26. Zhou Y, Wang SY, Yang XK, et al. Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells. Chin J Oncol. 2011;33:97-100.
27. Noguchi T, Kato T, Wang L, et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res. 2012;72:1672-1682.
28. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278-287.
29. Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am. 2012;26:447-481.